In plain English
Moderna Inc. develops biologic medicines and related therapies, focusing on mRNA technology for vaccines and oncology treatments. The…
Equity · NASDAQ · USD
MRNA
Moderna Inc
$142.97
Today
−$2.58-1.77%
vs previous close
Quote
- Open
- $145.05
- High
- $147.50
- Low
- $140.50
- Prev close
- $145.55
- Sector
- Healthcare
- Industry
- Biotechnology
- Size
- Mid-cap
- Market cap
- $58.1B
- Shares out
- 396.8M
- Country
- US
- IPO
- Dec 7, 2018
- Exchange
- NASDAQ
- Website
- modernatx.com
Price chart Pro
Loading chart…
Loading chart…
Company briefing
What MRNA is
Plain English context — why the name shows up in the news, and what to watch next. Not a tip.
Latest on this name
Insights & deeper context
24 recent cards — open any for the full deeper dive.
Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
In brief
Positive Phase 3 results for a personalized mRNA cancer vaccine could ignite a new biotech boom beyond obesity drugs, boosting genomics and precision‑medicine ETFs.
Nvidia's Best Day Since April 2025, Cybersecurity Stocks Go Vertical: Stock Market Today
In brief
Nvidia’s bullish revenue outlook and a surge in cybersecurity stocks lift tech, making the Nasdaq and tech ETFs the day’s leaders.
Moderna Borrows $2 Billion To Expand Oncology Business
In brief
Moderna’s $2 billion convertible note deal aims to fund oncology growth while managing dilution, but the market reacted negatively, pushing shares down.
Moderna Stock Edges Higher Tuesday: What's Happening?
In brief
Moderna’s stock gains are driven by a breakthrough melanoma trial and analyst upgrades that boost its oncology outlook.
What’s Going On With Tempus AI Stock on Monday?
In brief
TEM’s recent pullback reflects a re‑pricing of its momentum‑driven rally, with FDA clearance adding a new product but analyst sentiment remaining split.
Benzinga Bulls and Bears: Ross, Moderna, Webull
In brief
Ross and Webull’s Q2 beats lift guidance and confidence, while Moderna’s profit‑taking and Berkshire’s Alphabet stake shift focus toward tech and retail resilience amid higher yields.
MRNA, SPCX, MSTR and More: 5 Stocks Investors Couldn't Stop Buzzing About This Week
In brief
Retail hype turned corporate news into sharp price swings across biotech, retail, AI, and space stocks this week.
Bessent's Bond Band-Aid, Bitcoin's Best Week Since 2023: This Week on Wall Street
In brief
The Treasury’s buyback announcement briefly lowered long‑term yields, sparking a crypto rally, but the effect faded; Walmart’s earnings miss and Moderna’s breakthrough vaccine drove sharp moves in their respective stocks.
If You Invested $1,000 In Moderna Stock at IPO, Here's How Much You'd Have Now
In brief
Moderna’s Phase 3 cancer vaccine win has revived the stock, underscoring the company’s shift from pandemic focus to broader mRNA therapeutics.
COVID-19 Made Moderna Famous: Cancer Could Define Its Future
In brief
Moderna’s Phase 3 melanoma win could be the catalyst that turns its mRNA platform into a sustainable oncology business, redefining its future beyond COVID‑19.
QUICK SPARK: Moderna Stock Drops 25%, Eyes Worst Day in Company's History
In brief
Moderna’s record rally was quickly erased by a 25.69% slide, reflecting the high stakes of its first Phase 3 mRNA cancer therapy and the weight of its short‑interest profile.
Why Iovance Biotherapeutics Stock Hit 52-Week High
In brief
Iovance’s 52‑week high is fueled by industry momentum from Moderna and Merck’s breakthrough data, not by new company announcements, but by the broader confidence in individualized cancer therapies.
Bessent's Bond Rescue Fizzles, Walmart Craters 9%: Stock Market Today
In brief
Bond‑buyback fizzles, yields rebound, and Walmart’s sales slump sends a bearish signal to consumer stocks.
Moderna's Intismeran Close to Keytruda Style Oncology Opportunity: Analyst
In brief
Intismeran’s strong interim data lift its approval odds and open a Keytruda‑style revenue stream, but investors remain cautious about its broader oncology potential.
Pharma Bro Admits 'Playing Around' With MRNA Short At $80 Before it Exploded 177% Following Cancer Vax Trials— ‘I Bet You a Bunch of People Got Fired’
In brief
Moderna’s cancer‑vaccine win triggered a 177% stock jump that caught many traders off‑balance, exposing gaps in biotech positioning.
Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Fall as Trump Launches ‘Operation Economic Fury’ on Iran— BULL, WMT, MRK Stock in Focus (UPDATED)
In brief
Geopolitical tension over Iran and a likely Fed rate hike pushed markets lower, but economic data and sector moves keep volatility high.
Why Is Tempus AI Stock Gaining Thursday?
In brief
Positive melanoma trial results are lifting Tempus AI shares as investors weigh the strategic value of its planned Personalis acquisition.
Okta To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Thursday
In brief
Analysts are broadly bullish, lifting price targets across tech and biotech, with Okta’s target jump to $170 indicating strong upside potential.
Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why
In brief
Sector rally on mRNA cancer therapy news lifts biotech names, but RXRX’s insider share sale tempers its upside.
Dow Gains Over 100 Points: Investor Sentiment Improves, Fear Index In ‘Greed’ Zone
In brief
U.S. stocks rose on lower yields and a bullish sentiment index, but mixed earnings hint at uneven strength across sectors.
Moderna Stock Cools Off After-Hours, Following Massive 177% Cancer Vaccine Rally — Merck, Pfizer and BioNTech Among mRNA Names Trending Tonight
In brief
Positive Phase 3 cancer trial data for intismeran led to a sharp intraday rally in mRNA stocks, but after‑hours trading saw a pullback as investors took profits or reassessed upside.
Elon Musk Says mRNA Has 'Tremendous Promise,' Turning Disease Into a 'Software Problem,' as Moderna Stock Rockets 177% on Cancer Vaccine Breakthrough
In brief
Moderna and Merck’s Phase 3 melanoma vaccine win validates mRNA oncology, sending shares soaring and boosting confidence in the platform’s future.
Moderna, Webull, Bitmine Immersion, Strategy and Merck: Why These 5 Stocks Are on Investors' Radars Today
In brief
Moderna’s Phase‑3 win could pivot the company toward oncology, while Webull, Bitmine, Strategy, and Merck all benefited from strong earnings or market sentiment, driving significant intraday gains.
Trump Adds to Wealth With Moderna Stock Gains: Here’s How Much President Made
In brief
Moderna’s Phase 3 win fuels a 100%+ stock rally, boosting President Trump’s blind‑trust holdings by up to $91k and underscoring the biotech sector’s growth prospects amid political scrutiny.
Filings & reports
SEC and filing-linked cards
No filings tagged yet
Filing-linked cards for MRNA will show up here when available.
Indexes like the S&P 500 are shown via liquid ETFs (e.g. SPY). Company profile and quotes use live market data when available.